Bioton

Biomed-Lublin signed a distribution agreement with Bioton for the sale of Distreptaza in Poland, valued at approximately PLN 45 million, valid until end of 2022. Biomed also announced a new production line for Distreptaza will start in Q3 2018.

Biomed-Lublin signed a cooperation agreement with Bioton for the sale and distribution of Distreptaza in Poland until end of 2022, with a total estimated value of about 45 million PLN. Biomed will also launch a new Distreptaza production line in Q3 2018, doubling capacity.